Jing Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Yu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Kunwei Shen
Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
5 shared publications - Xiaosong Chen
Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China
5 shared publications - Ou Huang
Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Jiayi Wu
Department of General Surgery Comprehensive Breast Health Center Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
2 shared publications - Albert Lladó
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
1 shared publication Budong Zhu
Peking University Cancer Hospital and Institute
1 shared publication
Latest Publications
- 18 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (1) , 170-174
Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study
Although reduced mortality associated with moderate-to-vigorous physical activity has been reported among cancer survivors, the benefits of a concentrated physical activity pattern remain unclear. This prospective cohort study included 6075 cancer survivors from the UK Biobank accelerometry dataset: 2390 (39.3%) were inactive (<150 minutes/week), 1295 (21.3%) were active concentrated (≥150 minutes/week and achieved ≥50% total moderate-to-vigorous physical activity within 1-2 days), and 2390 (39.3%) were active regular (≥150 minutes/week but other than concentrated). After a median follow-up of 8 years (interquartile range [IQR] = 7.5 to 8.5 years), 634 deaths occurred. Active concentrated and regular patterns were associated with similar reduced all-cause mortality (hazard ratio [HR] = 0.72, 95% CI = 0.60 to 0.86; HR = 0.71, 95% CI = 0.56 to 0.89) and noncancer mortality (HR = 0.66, 95% CI = 0.47 to 0.92; HR = 0.56, 95% CI = 0.35 to 0.89). These findings highlight the concentrated physical activity pattern as a lifestyle intervention for cancer survivors.
- 18 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (1) , 170-174
Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study
Although reduced mortality associated with moderate-to-vigorous physical activity has been reported among cancer survivors, the benefits of a concentrated physical activity pattern remain unclear. This prospective cohort study included 6075 cancer survivors from the UK Biobank accelerometry dataset: 2390 (39.3%) were inactive (<150 minutes/week), 1295 (21.3%) were active concentrated (≥150 minutes/week and achieved ≥50% total moderate-to-vigorous physical activity within 1-2 days), and 2390 (39.3%) were active regular (≥150 minutes/week but other than concentrated). After a median follow-up of 8 years (interquartile range [IQR] = 7.5 to 8.5 years), 634 deaths occurred. Active concentrated and regular patterns were associated with similar reduced all-cause mortality (hazard ratio [HR] = 0.72, 95% CI = 0.60 to 0.86; HR = 0.71, 95% CI = 0.56 to 0.89) and noncancer mortality (HR = 0.66, 95% CI = 0.47 to 0.92; HR = 0.56, 95% CI = 0.35 to 0.89). These findings highlight the concentrated physical activity pattern as a lifestyle intervention for cancer survivors.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Breast Cancer
- Vol. 27 (3) , 163-175
The 21-Gene Recurrence Score Assay Improved Multidisciplinary Treatment Compliance in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: An Analysis of 2,323 Patients
Li L, et al. J Breast Cancer. 2024 Apr;27:e13. https://doi.org/10.4048/jbc.2023.0248
- 1 January 2024
- Published by XMLink in Journal of Breast Cancer
- Vol. 27 (3) , 163-175
Open AccessThe 21-Gene Recurrence Score Assay Improved Multidisciplinary Treatment Compliance in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: An Analysis of 2,323 Patients
Li L, et al. J Breast Cancer. 2024 Apr;27:e13. https://doi.org/10.4048/jbc.2023.0248
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Brain Arginine Metabolism in Early‐onset Alzheimer’s Disease and Frontotemporal Dementia
Background: The semi‐essential amino acid L‐arginine is metabolically versatile with a number of bioactive metabolites that are involved in synaptic plasticity, learning and memory, cerebral blood flow and microtubule stabilization processes. Altered brain arginine metabolism is evident in patients with late‐onset Alzheimer’s disease and has been implicated in the disease pathogenesis. However, the brain arginine metabolic profile is yet to be investigated in early‐onset Alzheimer’s disease (EOAD) and frontotemporal dementia (FTD).Method: Using high performance liquid chromatography and liquid chromatography/mass spectrometry, we measured the concentrations of L‐arginine and its downstream metabolites L‐citrulline, L‐ornithine, agmatine, glutamate, glutamine, GABA, putrescine, spermidine and spermine in the hippocampus and frontal and temporal cortices from EOAD (n = 27‐28/region), FTD (n = 27‐31/region) and control (n = 9‐17/region) cases.Result: There were significantly reduced levels of L‐ornithine in all three brain regions in both groups of dementia cases compared to the controls. Furthermore, the putrescine levels were significantly reduced in all brain regions examined in the FTD cases, and in the temporal cortex and hippocampus of the EOAD cases. In the hippocampus, there were increased L‐arginine levels, but decreased agmatine levels, in both the EOAD and FTD cases relative to the controls.Conclusion: This study demonstrates for the first time that brain arginine metabolism is altered similarly in both EOAD and FTD cases, and therefore suggests that altered L‐arginine metabolism may be a common mechanism involved in the neurodegenerative processes in these two early‐onset dementias. Further research is required to investigate the mechanisms for these metabolite changes and to explore the therapeutic potential of targeting L‐arginine metabolism in EOAD and FTD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessBrain Arginine Metabolism in Early‐onset Alzheimer’s Disease and Frontotemporal Dementia
Background: The semi‐essential amino acid L‐arginine is metabolically versatile with a number of bioactive metabolites that are involved in synaptic plasticity, learning and memory, cerebral blood flow and microtubule stabilization processes. Altered brain arginine metabolism is evident in patients with late‐onset Alzheimer’s disease and has been implicated in the disease pathogenesis. However, the brain arginine metabolic profile is yet to be investigated in early‐onset Alzheimer’s disease (EOAD) and frontotemporal dementia (FTD).Method: Using high performance liquid chromatography and liquid chromatography/mass spectrometry, we measured the concentrations of L‐arginine and its downstream metabolites L‐citrulline, L‐ornithine, agmatine, glutamate, glutamine, GABA, putrescine, spermidine and spermine in the hippocampus and frontal and temporal cortices from EOAD (n = 27‐28/region), FTD (n = 27‐31/region) and control (n = 9‐17/region) cases.Result: There were significantly reduced levels of L‐ornithine in all three brain regions in both groups of dementia cases compared to the controls. Furthermore, the putrescine levels were significantly reduced in all brain regions examined in the FTD cases, and in the temporal cortex and hippocampus of the EOAD cases. In the hippocampus, there were increased L‐arginine levels, but decreased agmatine levels, in both the EOAD and FTD cases relative to the controls.Conclusion: This study demonstrates for the first time that brain arginine metabolism is altered similarly in both EOAD and FTD cases, and therefore suggests that altered L‐arginine metabolism may be a common mechanism involved in the neurodegenerative processes in these two early‐onset dementias. Further research is required to investigate the mechanisms for these metabolite changes and to explore the therapeutic potential of targeting L‐arginine metabolism in EOAD and FTD.
- Open Access
- 16 September 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (9) , e27576
A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study
Background: Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery. Objective: This study aims to investigate the influence factors of treatment nonadherence and to determine whether this smartphone-based app can improve the compliance rate with MDTs. Methods: Patients who had received a diagnosis of invasive breast cancer and had undergone MDT between March 2013 and May 2019 were included. Patients were classified into 3 groups: Pre-App cohort (November 2017, before the launch of the app); App nonused, cohort (after November 2017 but not using the app); and App used cohort (after November 2017 and using the app). Univariate and multivariate analyses were performed to identify the factors related to MDT adherence. Compliance with specific adjuvant treatments, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, was also evaluated. Results: A total of 4475 patients were included, with Pre-App, App nonused, and App used cohorts comprising 2966 (66.28%), 861 (19.24%), and 648 (14.48%) patients, respectively. Overall, 15.53% (695/4475) patients did not receive MDT recommendations; the noncompliance rate ranged from 27.4% (75/273) in 2013 to 8.8% (44/500) in 2019. Multivariate analysis demonstrated that app use was independently associated with adherence to adjuvant treatment. Compared with the patients in the Pre-App cohort, patients in the App used cohort were less likely to deviate from MDT recommendations (odds ratio [OR] 0.61, 95% CI 0.43-0.87; P=.007); no significant difference was found in the App nonused cohort (P=.77). Moreover, app use decreased the noncompliance rate for adjuvant chemotherapy (OR 0.41, 95% CI 0.27-0.65; P<.001) and radiotherapy (OR 0.49, 95% CI 0.25-0.96; P=.04), but not for anti-HER2 therapy (P=.76) or endocrine therapy (P=.39). Conclusions: This smartphone-based app can increase MDT adherence in patients undergoing adjuvant therapy; this was more obvious for adjuvant chemotherapy and radiotherapy.
- 16 September 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (9) , e27576
Open AccessA Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study
Background: Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery. Objective: This study aims to investigate the influence factors of treatment nonadherence and to determine whether this smartphone-based app can improve the compliance rate with MDTs. Methods: Patients who had received a diagnosis of invasive breast cancer and had undergone MDT between March 2013 and May 2019 were included. Patients were classified into 3 groups: Pre-App cohort (November 2017, before the launch of the app); App nonused, cohort (after November 2017 but not using the app); and App used cohort (after November 2017 and using the app). Univariate and multivariate analyses were performed to identify the factors related to MDT adherence. Compliance with specific adjuvant treatments, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, was also evaluated. Results: A total of 4475 patients were included, with Pre-App, App nonused, and App used cohorts comprising 2966 (66.28%), 861 (19.24%), and 648 (14.48%) patients, respectively. Overall, 15.53% (695/4475) patients did not receive MDT recommendations; the noncompliance rate ranged from 27.4% (75/273) in 2013 to 8.8% (44/500) in 2019. Multivariate analysis demonstrated that app use was independently associated with adherence to adjuvant treatment. Compared with the patients in the Pre-App cohort, patients in the App used cohort were less likely to deviate from MDT recommendations (odds ratio [OR] 0.61, 95% CI 0.43-0.87; P=.007); no significant difference was found in the App nonused cohort (P=.77). Moreover, app use decreased the noncompliance rate for adjuvant chemotherapy (OR 0.41, 95% CI 0.27-0.65; P<.001) and radiotherapy (OR 0.49, 95% CI 0.25-0.96; P=.04), but not for anti-HER2 therapy (P=.76) or endocrine therapy (P=.39). Conclusions: This smartphone-based app can increase MDT adherence in patients undergoing adjuvant therapy; this was more obvious for adjuvant chemotherapy and radiotherapy.
- Open Access
- 15 June 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-10
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Background: The 21-gene recurrence score (RS) can predict chemotherapy benefit in estrogen receptor-positive, human epidermal growth factor receptor-2-negative (ER+/HER2-) early breast cancer patients. Age would influence the interaction between RS and chemotherapy effect. The current study aimed to determine RS thresholds which were predictive of chemotherapy benefit in young and old women, respectively.Methods: Patients diagnosed with pN0–1, ER+/HER2- breast cancer between 2009 and 2016 were retrospectively reviewed. Propensity score matching was performed according to chemotherapy usage. After stratifying patients with different cutoffs of age, the RS threshold indicating chemotherapy benefit in each age strata were determined by cox proportional hazard models.Results: A total of 1227 patients were included. The median age was 58 years and the median RS was 24. After matching, the RS thresholds suggesting chemotherapy benefit varied with age. For patients ≤55 years, chemotherapy benefit was observed in those having RS > 25 (P = 0.03), with 4-year invasive disease-free survival (IDFS) of 97.0 and 89.3% in patients receiving chemotherapy or not. While patients derived no benefit from chemotherapy if they had RS ≤25 (P = 0.66, 4-year IDFS: 95.3% vs. 94.6%). For patients > 55 years, adjuvant chemotherapy was associated with better prognosis in those with RS > 36 (P = 0.014, 4-year IDFS: 94.7% vs. 76.2%), but not in those having RS ≤36 (P = 0.13, 4-year IDFS: 92.3% vs. 95.8%).Conclusions: Old patients need higher RS thresholds to demonstrate the chemotherapy benefit. Further efforts are warranted to investigate the association between age and predictive RS thresholds.
- 15 June 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-10
Open AccessEfficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Background: The 21-gene recurrence score (RS) can predict chemotherapy benefit in estrogen receptor-positive, human epidermal growth factor receptor-2-negative (ER+/HER2-) early breast cancer patients. Age would influence the interaction between RS and chemotherapy effect. The current study aimed to determine RS thresholds which were predictive of chemotherapy benefit in young and old women, respectively.Methods: Patients diagnosed with pN0–1, ER+/HER2- breast cancer between 2009 and 2016 were retrospectively reviewed. Propensity score matching was performed according to chemotherapy usage. After stratifying patients with different cutoffs of age, the RS threshold indicating chemotherapy benefit in each age strata were determined by cox proportional hazard models.Results: A total of 1227 patients were included. The median age was 58 years and the median RS was 24. After matching, the RS thresholds suggesting chemotherapy benefit varied with age. For patients ≤55 years, chemotherapy benefit was observed in those having RS > 25 (P = 0.03), with 4-year invasive disease-free survival (IDFS) of 97.0 and 89.3% in patients receiving chemotherapy or not. While patients derived no benefit from chemotherapy if they had RS ≤25 (P = 0.66, 4-year IDFS: 95.3% vs. 94.6%). For patients > 55 years, adjuvant chemotherapy was associated with better prognosis in those with RS > 36 (P = 0.014, 4-year IDFS: 94.7% vs. 76.2%), but not in those having RS ≤36 (P = 0.13, 4-year IDFS: 92.3% vs. 95.8%).Conclusions: Old patients need higher RS thresholds to demonstrate the chemotherapy benefit. Further efforts are warranted to investigate the association between age and predictive RS thresholds.
- Open Access
- 28 January 2021
- Published by JMIR Publications Inc. in JMIR Preprints
A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study (Preprint)
BACKGROUND Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery. OBJECTIVE This study aims to investigate the influence factors of treatment nonadherence and to determine whether this smartphone-based app can improve the compliance rate with MDTs. METHODS Patients who had received a diagnosis of invasive breast cancer and had undergone MDT between March 2013 and May 2019 were included. Patients were classified into 3 groups: Pre-App cohort (November 2017, before the launch of the app); App nonused, cohort (after November 2017 but not using the app); and App used cohort (after November 2017 and using the app). Univariate and multivariate analyses were performed to identify the factors related to MDT adherence. Compliance with specific adjuvant treatments, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, was also evaluated. RESULTS A total of 4475 patients were included, with Pre-App, App nonused, and App used cohorts comprising 2966 (66.28%), 861 (19.24%), and 648 (14.48%) patients, respectively. Overall, 15.53% (695/4475) patients did not receive MDT recommendations; the noncompliance rate ranged from 27.4% (75/273) in 2013 to 8.8% (44/500) in 2019. Multivariate analysis demonstrated that app use was independently associated with adherence to adjuvant treatment. Compared with the patients in the Pre-App cohort, patients in the App used cohort were less likely to deviate from MDT recommendations (odds ratio [OR] 0.61, 95% CI 0.43-0.87; P=.007); no significant difference was found in the App nonused cohort (P=.77). Moreover, app use decreased the noncompliance rate for adjuvant chemotherapy (OR 0.41, 95% CI 0.27-0.65; P<.001) and radiotherapy (OR 0.49, 95% CI 0.25-0.96; P=.04), but not for anti-HER2 therapy (P=.76) or endocrine therapy (P=.39). CONCLUSIONS This smartphone-based app can increase MDT adherence in patients undergoing adjuvant therapy; this was more obvious for adjuvant chemotherapy and radiotherapy.
- 28 January 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study (Preprint)
BACKGROUND Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery. OBJECTIVE This study aims to investigate the influence factors of treatment nonadherence and to determine whether this smartphone-based app can improve the compliance rate with MDTs. METHODS Patients who had received a diagnosis of invasive breast cancer and had undergone MDT between March 2013 and May 2019 were included. Patients were classified into 3 groups: Pre-App cohort (November 2017, before the launch of the app); App nonused, cohort (after November 2017 but not using the app); and App used cohort (after November 2017 and using the app). Univariate and multivariate analyses were performed to identify the factors related to MDT adherence. Compliance with specific adjuvant treatments, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, was also evaluated. RESULTS A total of 4475 patients were included, with Pre-App, App nonused, and App used cohorts comprising 2966 (66.28%), 861 (19.24%), and 648 (14.48%) patients, respectively. Overall, 15.53% (695/4475) patients did not receive MDT recommendations; the noncompliance rate ranged from 27.4% (75/273) in 2013 to 8.8% (44/500) in 2019. Multivariate analysis demonstrated that app use was independently associated with adherence to adjuvant treatment. Compared with the patients in the Pre-App cohort, patients in the App used cohort were less likely to deviate from MDT recommendations (odds ratio [OR] 0.61, 95% CI 0.43-0.87; P=.007); no significant difference was found in the App nonused cohort (P=.77). Moreover, app use decreased the noncompliance rate for adjuvant chemotherapy (OR 0.41, 95% CI 0.27-0.65; P<.001) and radiotherapy (OR 0.49, 95% CI 0.25-0.96; P=.04), but not for anti-HER2 therapy (P=.76) or endocrine therapy (P=.39). CONCLUSIONS This smartphone-based app can increase MDT adherence in patients undergoing adjuvant therapy; this was more obvious for adjuvant chemotherapy and radiotherapy.
- 17 March 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (7) , 1197-1203
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC. 79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ2 test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes. There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004). CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.
- 17 March 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (7) , 1197-1203
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC. 79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ2 test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes. There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004). CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.